Key Points
- Insider sale: Janet Jill Hopkins sold 20,401 shares on Feb. 17 at an average price of $5.06 for a total of $103,229.06, reducing her stake by 8.07% to 232,284 shares valued at $1,175,357.04.
- Multiple other insiders (including Los Pinos Elisabet De, Amy Elazzouzi, Mark Plavsic and Conor Kilroy) also sold shares recently, and the stock is trading down ~5.7%, signaling notable insider selling pressure.
- Aura trades around $5.25 with a market cap of $333.38M and moving averages of $5.60 (50-day) and $5.97 (200-day); analysts' consensus is a Moderate Buy with an average price target of $20.50.
Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) SVP Amy Elazzouzi sold 8,549 shares of the company's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $5.06, for a total value of $43,257.94. Following the completion of the sale, the senior vice president owned 75,532 shares of the company's stock, valued at $382,191.92. This represents a 10.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Amy Elazzouzi also recently made the following trade(s):
- On Tuesday, January 20th, Amy Elazzouzi sold 1,581 shares of Aura Biosciences stock. The stock was sold at an average price of $4.86, for a total value of $7,683.66.
Aura Biosciences Price Performance
Shares of AURA stock opened at $5.25 on Wednesday. The stock has a market cap of $333.38 million, a PE ratio of -2.71 and a beta of 0.46. The stock has a 50-day moving average of $5.60 and a 200-day moving average of $5.97. Aura Biosciences, Inc. has a one year low of $4.34 and a one year high of $8.03.
Institutional Investors Weigh In On Aura Biosciences
Several institutional investors have recently added to or reduced their stakes in AURA. Dynamic Technology Lab Private Ltd bought a new stake in Aura Biosciences in the 1st quarter valued at $137,000. Atria Investments Inc acquired a new position in shares of Aura Biosciences during the second quarter worth about $190,000. Levin Capital Strategies L.P. grew its holdings in shares of Aura Biosciences by 9.9% during the second quarter. Levin Capital Strategies L.P. now owns 1,495,560 shares of the company's stock worth $9,362,000 after buying an additional 134,792 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Aura Biosciences by 5.9% during the second quarter. Franklin Resources Inc. now owns 2,340,810 shares of the company's stock worth $14,653,000 after buying an additional 130,221 shares in the last quarter. Finally, Invesco Ltd. acquired a new stake in Aura Biosciences in the 2nd quarter valued at approximately $76,000. 96.75% of the stock is owned by institutional investors.
Analyst Ratings Changes
Several research firms have weighed in on AURA. Weiss Ratings reiterated a "sell (d-)" rating on shares of Aura Biosciences in a report on Monday, December 29th. Evercore initiated coverage on shares of Aura Biosciences in a research report on Tuesday, November 25th. They issued an "outperform" rating for the company. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $20.50.
View Our Latest Research Report on AURA
Trending Headlines about Aura Biosciences
Here are the key news stories impacting Aura Biosciences this week:
- Neutral Sentiment: Short-interest entries on Feb. 16–17 report a "large/significant increase" but show 0 shares and NaN changes, indicating likely data/reporting errors rather than genuine new short activity. This is an uncertain/neutral factor.
- Negative Sentiment: Insider sale — Los Pinos Elisabet De (insider) sold 47,648 shares at an average ~$5.06 (reducing her stake ~10.42%). SEC filing: Los Pinos Elisabet De sale
- Negative Sentiment: Insider sale — Amy Elazzouzi (SVP) sold 8,549 shares at an average ~$5.06 (reducing her stake ~10.17%). SEC filing: Amy Elazzouzi sale
- Negative Sentiment: Insider sale — Janet Jill Hopkins sold 20,401 shares at an average ~$5.06 (reducing her stake ~8.07%). SEC filing: Janet Jill Hopkins sale
- Negative Sentiment: Insider sale — Mark Plavsic (CTO) sold 15,890 shares at an average ~$5.05 (reducing his stake ~8.05%). SEC filing: Mark Plavsic sale
- Negative Sentiment: Insider sale — Conor Kilroy sold 12,079 shares at an average ~$5.05 (reducing his stake ~6.74%). SEC filing: Conor Kilroy sale
About Aura Biosciences
(
Get Free Report)
Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company's platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.
The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
